PE20260309A1 - Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo - Google Patents

Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo

Info

Publication number
PE20260309A1
PE20260309A1 PE2025003120A PE2025003120A PE20260309A1 PE 20260309 A1 PE20260309 A1 PE 20260309A1 PE 2025003120 A PE2025003120 A PE 2025003120A PE 2025003120 A PE2025003120 A PE 2025003120A PE 20260309 A1 PE20260309 A1 PE 20260309A1
Authority
PE
Peru
Prior art keywords
crystalline forms
pharmaceutical compositions
salts
salt
organic compound
Prior art date
Application number
PE2025003120A
Other languages
English (en)
Spanish (es)
Inventor
Jacob Sizemore
Syed Altaf
Abira Ramakrishnan
Shijie Zhang
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of PE20260309A1 publication Critical patent/PE20260309A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PE2025003120A 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo PE20260309A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
PE20260309A1 true PE20260309A1 (es) 2026-02-11

Family

ID=69185721

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2025003120A PE20260309A1 (es) 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo
PE2021001052A PE20212197A1 (es) 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2021001052A PE20212197A1 (es) 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo

Country Status (22)

Country Link
US (2) US12297179B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898597A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022515239A (cg-RX-API-DMAC7.html)
KR (1) KR20220035022A (cg-RX-API-DMAC7.html)
CN (1) CN113508108B (cg-RX-API-DMAC7.html)
AU (1) AU2019403396B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012305A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021001640A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009309A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210394A (cg-RX-API-DMAC7.html)
GE (2) GEP20247683B (cg-RX-API-DMAC7.html)
IL (1) IL284218B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210147A1 (cg-RX-API-DMAC7.html)
MA (1) MA54541A (cg-RX-API-DMAC7.html)
MX (1) MX2021007536A (cg-RX-API-DMAC7.html)
NI (1) NI202100055A (cg-RX-API-DMAC7.html)
PE (2) PE20260309A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551495A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106526UA (cg-RX-API-DMAC7.html)
TW (1) TWI875727B (cg-RX-API-DMAC7.html)
UA (1) UA130491C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020132471A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7622000A (en) * 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
MX2010010300A (es) 2008-03-19 2010-10-26 Osi Pharm Inc Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
US20230285364A1 (en) * 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Also Published As

Publication number Publication date
IL284218A (en) 2021-08-31
CO2021009309A2 (es) 2021-10-29
AU2019403396B2 (en) 2024-12-12
KR20220035022A (ko) 2022-03-21
NI202100055A (es) 2021-12-01
EP3898597A1 (en) 2021-10-27
JP2026001058A (ja) 2026-01-06
US20250270175A1 (en) 2025-08-28
GEP20247683B (en) 2024-10-28
GEAP202415700A (en) 2024-05-13
PE20212197A1 (es) 2021-11-16
UA130491C2 (uk) 2026-03-04
SG11202106526UA (en) 2021-07-29
JOP20210147A1 (ar) 2023-01-30
JP2022515239A (ja) 2022-02-17
MX2021007536A (es) 2021-09-23
MA54541A (fr) 2022-03-09
PH12021551495A1 (en) 2022-03-07
CA3124401A1 (en) 2020-06-25
JP7749080B2 (ja) 2025-10-03
CN113508108A (zh) 2021-10-15
US20220055995A1 (en) 2022-02-24
BR112021012305A2 (pt) 2021-10-05
CL2021001640A1 (es) 2022-06-03
WO2020132471A1 (en) 2020-06-25
IL284218B2 (en) 2026-05-01
WO2020132471A8 (en) 2020-08-06
US12297179B2 (en) 2025-05-13
CN113508108B (zh) 2024-12-24
CR20210394A (es) 2021-12-13
TW202039448A (zh) 2020-11-01
IL284218B1 (en) 2026-01-01
JP2024161431A (ja) 2024-11-19
TWI875727B (zh) 2025-03-11
AU2019403396A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
CU20210009A7 (es) Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3)
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
JOP20190217A1 (ar) مركبات جديدة كمثبطات أوتوتاكسين وتركيبات صيدلانية تشتمل على هذه المركبات
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201891313A1 (ru) Замещенные гидроксиалкиламинами и гидроксициклоалкиламинами соединения диаминарилсульфонамидов с избирательной активностью в потенциалзависимых натриевых каналах
MX2021011606A (es) Compuestos dirigidos a prmt5.
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201691302A1 (ru) Новые гетероциклические соединения
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
CO2021009309A2 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
MD4626B1 (ro) Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX390748B (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
EA201291246A1 (ru) Конденсированные бициклические ингибиторы киназы
EA201691141A1 (ru) Соединения против ccr6
EA201700042A1 (ru) Соединения имидазопиридазина
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.